secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2026-10-07T13:00:14+00:00
Accession:  0001193125-26-416251
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Ultragenyx to sell FDA-awarded PRV for $210M cash; 20% of proceeds owed to NIH
------------------------------------------------------------------------------

- Asset purchase agreement signed Oct 6, 2026 to sell the Rare Pediatric Disease Priority Review Voucher awarded by FDA on Aug 19, 2026.
- $210 million payable in cash to Ultragenyx at closing; no buyer named in the filing.
- 20% of gross proceeds (~$42M) payable to the NIH under a patent license agreement dated Dec 10, 2018.
- PRV stemmed from FDA approval of GENGLYCOS (pariglasgene brecaparvovec-opnr), or DTX401, for glycogen storage disease type Ia in patients 8 and older.
- Closing subject to customary conditions, including expiry or termination of the HSR waiting period; agreement to be filed with the FY2026 10-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000119312526416251/0001193125-26-416251-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000119312526416251/rare-20261006.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-416251

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer